STOCK TITAN
  1. Home
  2. News
  3. BNOX

Bionomics Ltd. - BNOX STOCK NEWS

Welcome to our dedicated news page for Bionomics Ltd. (Ticker: BNOX), a resource for investors and traders seeking the latest updates and insights on Bionomics Ltd..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bionomics Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bionomics Ltd.'s position in the market.

News
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder
Rhea-AI Summary
Bionomics (Nasdaq: BNOX) announced positive Phase 2b trial results for BNC210 in treating post-traumatic stress disorder (PTSD), showing statistically significant improvements with a favorable safety profile. BNC210 demonstrated rapid onset of clinical efficacy and sustained effects, meeting primary and secondary endpoints. The trial data supports BNC210 as a potential highly differentiated treatment with a novel mechanism of action, positioning it as a promising therapy for PTSD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.98%
Tags
clinical trial
-
News
Bionomics to Present at the 2024 BIO CEO & Investor Conference
Rhea-AI Summary
Bionomics Limited (BNOX) to present at 2024 BIO CEO & Investor Conference on February 27, 2024, providing updates on BNC210, a Phase 3 ready asset for social anxiety disorder and post-traumatic stress disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
conferences
-
News
Bionomics Provides a Review of 2023 and of 2024 Plans
Rhea-AI Summary
Bionomics Limited (Nasdaq: BNOX) announced positive Phase 2b data for BNC210 in treating PTSD and SAD, with plans for a registrational study and strategic partnerships. The Company also reported successful clinical trials, strategic partnerships, and financial highlights for 2023, with an optimistic outlook for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
none
News
Bionomics to Present at Biotech Showcase™ 2024
Rhea-AI Summary
Bionomics Limited (Nasdaq: BNOX) will provide an update on its leading asset BNC210 and their partnership strategy at the Biotech Showcase™ 2024 in San Francisco. Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics, will present an update on BNC210, a Phase 3 ready α7 nicotinic receptor negative allosteric modulator with the potential to be first- and best-in-class in social anxiety disorder and post-traumatic stress disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
conferences
-
News
Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting
Rhea-AI Summary
Bionomics Limited (BNOX) announced the psychometric analysis of Subjective Units of Distress Scale (SUDS) as a valid, reliable, and sensitive tool for assessing anxiety in social anxiety disorder (SAD) clinical trials. The presentation, held at the 2023 American College of Neuropsychopharmacology Annual Meeting, highlighted the successful Phase 2 PREVAIL trial of BNC210 in SAD, where BNC210 demonstrated reduced anxiety and was well tolerated. The company also agreed on the plan for a registrational study of BNC210 in SAD, with SUDS as the primary efficacy endpoint. The upcoming Phase 3 trial is expected to begin in Q1’24.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
none
-
News
Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
Rhea-AI Summary
Bionomics Limited announces positive topline results from its Phase 2b ATTUNE trial of BNC210 for the treatment of PTSD. The trial met its primary endpoint of a statistically significant reduction in total PTSD symptom severity at 12 weeks. Secondary endpoints showed improvements in depressive symptoms and sleep. The company plans to engage with the FDA to discuss the registrational path for BNC210 in PTSD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
242.13%
Tags
clinical trial
News
Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD
Rhea-AI Summary
Bionomics collaborates with MSD to develop α7 nAChR PAMs for Alzheimer's Disease treatment. MSD presents data on MK-4334, a candidate derived from Bionomics' BNC375, at a recent conference. BNC375 shows promising results in animal models. MSD funds research and development, generating $20M upfront and $10M milestone payment for Phase 1. Bionomics eligible for up to $465M in additional milestone payments and royalties on net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.14%
Tags
none
-
News
Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210
Rhea-AI Summary
The Phase 2b ATTUNE study of BNC210 for PTSD is completed, with topline results expected by September 2023. An EoPh2 meeting with the FDA is scheduled for September 2023 to review results from the Phase 2 PREVAIL study for SAD and discuss a Phase 3 program. Bionomics will delist from the Australian Securities Exchange on August 28, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.83%
Tags
clinical trial
-
News
Quarterly Activities and Cashflow Report
Rhea-AI Summary
Bionomics Limited (BNOX | BNO) Releases Quarterly Cashflow Report and Announces Key Clinical Trial Updates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.14%
Tags
none
News
Bionomics Announces Intention to Delist from the Australian Securities Exchange (ASX)
Rhea-AI Summary
Bionomics Limited has submitted a request to be removed from the official list of the ASX and focus on a primary listing on the NASDAQ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.92%
Tags
none
Stock BNOX logo
Bionomics Ltd.

Nasdaq:BNOX

BNOX Rankings

#5348 Ranked by Market Cap
#5138 Ranked by Stock Gains
N/A Ranked by Dividends

BNOX Stock Data

10.29M
1.28B
21.67%
2.42%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Australia
Thebarton

About BNOX

bionomics is a biopharmaceutical company dedicated to making better treatments for cancer, central nervous system disorders such as anxiety, depression and alzheimer's disease. our exceptionally talented team is driven by a shared commitment to make a difference in diseases with inadequate treatment options. we are in a strong growth phase with our world-class portfolio of promising drug candidates from early to advanced stages of clinical development. this portfolio is fed by highly productive drug discovery platforms which includes multicore®, our proprietary chemistry capability. at the core of our business is strategic partnering. we partner with large pharmaceutical companies to get our drugs through the later stages of development and into the market as rapidly as possible. this means we can focus our strengths in innovative drug discovery to extract as many "shots on goal"​ from our diverse pipeline in the quest to create the world's new blockbuster drugs. we have a passion for